

Torrent Pharmaceuticals Ltd.**TPL**

Corporate Office :
Torrent House,
Off Ashram Road,
Ahmedabad-380 009.
India.

Phone : (079) 26585090/
26583060

Fax : (079) 26582100

October 26, 2012

The Dy. General Manager (Listing Dept.)
Bombay Stock Exchange Limited
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

✓ The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Audited Financial Results and Unaudited Consolidated Financial Results for the Quarter and Half Year ended on 30th September, 2012.

We enclose herewith the following:

1. Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and half year ended on 30th September, 2012 as per clause 41 of the Listing Agreement, which were approved by the Board of Directors at its meeting held on 26th October, 2012.

In terms of clause 41(VI) (b) of the Listing Agreement, the Company will publish above Unaudited Consolidated Financial Results for the quarter and half year ended on 30th September, 2012. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.


2. Press Release on Financial Results as being submitted to the press media.

The above is for your information and record.

Thanking you,

Yours faithfully,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: A/a



Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
Heritage, 2nd Floor
New Capital Vidyanagar,
Off Ashoka Road,
Ahmedabad - 380 014

Tel. +91 (079) 27582542
+91 (079) 27582543
+91 (079) 66073100
Fax +91 (079) 27582551

AUDITORS' REPORT TO THE BOARD OF DIRECTORS OF TORRENT PHARMACEUTICALS LIMITED

1. We have audited the accompanying Statement of Financial Results ("the Statement") of **TORRENT PHARMACEUTICALS LIMITED** ("the Company") for the quarter and half year ended 30th September, 2012, being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges. This Statement has been prepared on the basis of the related interim financial statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express an opinion on the Statement, based on our audit of the related interim financial statement, which has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS-25) on Interim Financial Reporting notified under the Companies (Accounting Standards) Rules, 2006 and other accounting principles generally accepted in India.
2. We conducted our audit of the Statement in accordance with the auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the Statement is free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts and the disclosures in the Statement. An audit also includes assessing the accounting principles used and the significant estimates made by the Management, as well as evaluating the overall Statement presentation. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Clause 41 of the Listing Agreements with the Stock Exchanges and
 - (ii) gives a true and fair view of the net profit and other financial information of the Company for the quarter and half year ended 30th September, 2012.




Deloitte Haskins & Sells

Deloitte Haskins & Sells,
Chartered Accountants
Heritage, 3rd Floor,
Near: Gujarat Vidyapeeth
Off Ashram Road,
Ahmedabad - 380 014

Tel: +91 (079) 27582542
+91 (079) 27582543
+91 (079) 66071100
Fax: +91 (079) 27582551

4. Further, we also report that we have traced from the details furnished by the Management, the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings and the number of shares as well as the percentage of shares pledged/encumbered in respect of the aggregate amount of promoter and promoter group in terms of Clause 35 of the Listing Agreements and the particulars relating to the undisputed investor complaints.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Registration No. 117365W)



(Gaurav J. Shah)
Partner
Membership No. 35701

Place: Dahej, Gujarat
Date: 26th October, 2012

TORRENT PHARMACEUTICALS LIMITED

PART I						
[Rs. in Lacs except per share data]						
Statement of Standalone Audited Results for the Quarter and Half Year Ended 30-Sep-2012						
Particulars	Quarter ended			Half year ended		Year ended
	30-Sep-2012	30-Jun-2012	30-Sep-2011	30-Sep-2012	30-Sep-2011	31-Mar-2012
Income from operations						
Net sales (Net of excise duty) (see note 2)	66156	62011	48141	128167	95943	198669
Other operating income	2736	2899	2482	5635	5363	8935
Total income from operations (net)	68892	64910	50623	133802	101306	207604
Expenses						
Cost of materials consumed	18507	17606	14493	36113	29232	59017
Purchases of stock-in-trade	12952	11992	6938	24944	9849	25210
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5074)	(4879)	(1848)	(9953)	(2216)	(3596)
Employee benefits expense	8835	8803	7592	17638	15345	30905
Depreciation and amortisation expense	1630	1632	1523	3262	3091	6390
Other expenses	17918	17022	13183	34940	25120	56029
Total expenses	54768	52176	41981	106944	80421	173955
Profit from operations before other income, finance costs and exceptional items	14124	12734	8642	26858	20885	33649
Other income	5845	5790	1226	11635	2512	13519
Profit from ordinary activities before finance costs and exceptional items	19969	18524	9868	38493	23397	47168
Finance costs	949	1043	989	1992	2009	3978
Profit from ordinary activities after finance costs but before exceptional items	19020	17481	8879	36501	21388	43190
Exceptional items	-	-	-	-	-	6120
Profit from ordinary activities before tax	19020	17481	8879	36501	21388	37070
Tax expense	2809	2729	1856	5538	4421	5945
Net profit for the period	16211	14752	7023	30963	16967	31125
Paid-up equity share capital (Face value of Rs.5 each)	4231	4231	4231	4231	4231	4231
Reserves excluding revaluation reserves	-	-	-	-	-	126218
Earnings per share (of Rs. 5/- each) (not annualised):						
Basic	19.15	17.44	8.30	36.59	20.05	36.79
Diluted	19.15	17.44	8.30	36.59	20.05	36.79



PART II						
Select Information for the Quarter and Half Year Ended 30-Sep-2012						
PARTICULARS OF SHAREHOLDING	Quarter ended			Half year ended		Year ended
	30-Sep-2012	30-Jun-2012	30-Sep-2011	30-Sep-2012	30-Sep-2011	31-Mar-2012
Public shareholding						
- Number of shares	24109500	24109500	24109500	24109500	24109500	24109500
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter group Shareholding						
a) Pledged/Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b) Non-encumbered						
- Number of shares	60501860	60501860	60501860	60501860	60501860	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended					
	30-Sep-2012					
Pending at the beginning of the quarter	Nil					
Received during the quarter	1					
Disposed of during the quarter	1					
Remaining unresolved at the end of the quarter	Nil					

Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 26-Oct-2012. There is no qualification in the Auditors Report on this statement of financial results.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

[Rs. in Lacs]

Particulars	Quarter ended			Half Year ended			Year ended
	30-Sep-2012	30-Sep-2011	Growth %	30-Sep-2012	30-Sep-2011	Growth %	31-Mar-2012
(A) Sales in India							
Branded sales	27425	23848	15%	55448	48491	14%	91670
Contract manufacture	5833	5514	2%	10384	11647	(11%)	24271
Others	225	225	-	576	348	-	1472
Total sales in India	33283	29587	12%	66408	60486	10%	117413
(B) Sales outside India	33073	18683	77%	62130	35680	74%	81736
Total sales (A+B)	66356	48270	37%	128538	96166	34%	199149
Less: Excise duty	200	129	-	371	223	-	480
Net sales	66156	48141	37%	128167	95943	34%	198669



3 Standalone Statement of Assets and Liabilities

Particulars	[Rs. in Lacs]	
	Unaudited	Audited
	As at 30-Sep-2012	As at 31-Mar-2012
EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	4231	4231
Reserves and surplus	161261	126218
Sub-total - Shareholders' funds	165492	130449
Non-current liabilities		
Long-term borrowings	23922	32206
Deferred tax liabilities (net)	6109	6317
Other long-term liabilities	10	45
Long-term provisions	6885	5965
Sub-total - Non-current liabilities	36926	44533
Current liabilities		
Short-term borrowings	6455	13812
Trade payables	50094	37340
Other current liabilities	23516	25737
Short-term provisions	4791	5967
Sub-total - Current liabilities	84856	82856
TOTAL - EQUITY AND LIABILITIES	287274	257838
ASSETS		
Non-current assets		
Fixed assets	70160	66317
Non-current investments	46190	39130
Long-term loans and advances	3550	5367
Other non-current assets	1824	4625
Sub-total - Non-current assets	121724	115439
Current assets		
Current investments	8125	8652
Inventories	57386	39312
Trade receivables	56559	40962
Cash and cash equivalents	16946	36669
Short-term loans and advances	14296	6296
Other current assets	12238	10508
Sub-total - Current assets	165550	142399
TOTAL - ASSETS	287274	257838

- 4 The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current period.
- 5 The Company has also prepared and published unaudited consolidated financial results for the quarter and half year ended 30-Sep-2012, which were subjected to limited review by statutory auditors of the Company.



Place : Dahanu, Gujarat
Date : 26-Oct-2012

.... Visit us at www.torrentpharma.com....

For TORRENT PHARMACEUTICALS LIMITED

SAMIR MEHTA
Executive Vice Chairman

Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
"Heritage", 1st Floor,
Near Gujarat Vidhyapeeth
Off Ashram Road
Ahmedabad - 380 014

Tel. +91 (079) 27542542
+91 (079) 27582143
+91 (079) 65673100
Fax. +91 (079) 27582551

AUDITORS' REPORT TO THE BOARD OF DIRECTORS OF TORRENT PHARMACEUTICALS LIMITED

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results ("the Statement") of **TORRENT PHARMACEUTICALS LIMITED** ("the Company"), its subsidiaries (the Company and its subsidiaries constitute "the Group") for the quarter and half year ended 30th September, 2012. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an opinion.
3. The Statement includes the results of the following subsidiaries:

(1) Zao Torrent Pharma, (2) Torrent Pharma GmbH, (3) Heumann Pharma GmbH & Co. Generica KG, (4) Torrent Do Brasil Ltda, (5) Torrent Pharma Philippines Inc., (6) Torrent Pharma Inc., (7) Laboratories Torrent S.A. de C.V., (8) Torrent Australasia Pty Ltd., (9) Heunet Pharma GmbH, (10) Norispharm GmbH, (11) Torrent Pharma Canada Inc., (12) Torrent Pharma (Thailand) Co., Limited, (13) Torrent Pharma S.R.L., (14) Torrent Pharma (UK) Limited, (15) Torrent Pharmaceuticals (Dahej), (16) Torrent Pharmaceuticals (Sikkim) and (17) Laboratories Torrent (Malaysia) Sdn. Bhd.
4. The financial results of fifteen subsidiaries which reflect the Company's share of revenue of Rs. 33,166 lacs for the quarter ended 30th September, 2012 and Rs. 65,272 lacs for the half year ended 30th September, 2012 and the Company's share of Loss after Tax of Rs. 4,178 lacs for the quarter ended 30th September, 2012 and Rs. 8,177 lacs for the half year ended 30th September, 2012 have not been reviewed by their auditors.




Deloitte Haskins & Sells

Deloitte Haskins & Sells
Chartered Accountants
"Harnag", 3rd Floor,
Near Gujarat Vidhyapeeth,
Old Ashram Road,
Ahmedabad - 380 014
Tel: +91 (079) 27582542
+91 (079) 27582543
+91 (079) 68025100
Fax: +91 (079) 27582551

5. Based on our review and subject to our comments in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the stock exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Further, we also report that we have traced from the details furnished by the Management, the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings and the number of shares as well as the percentage of shares pledged/encumbered in respect of the aggregate amount of promoter and promoter group in terms of Clause 35 of the Listing Agreements and the particulars relating to the undisputed investor complaints.

For DELOITTE HASKINS & SELLS
Chartered Accountants
(Registration No. 117365W)



(Gaurav J. Shah)
Partner
Membership No. 35701

Place: Dahej, Gujarat
Date: 26th October, 2012

TORRENT PHARMACEUTICALS LIMITED

[Rs. in Lacs except per share data]						
PART I - Statement of Consolidated Results for the Quarter and Half Year Ended 30-Sep-2012						
Particulars	Quarter ended (Unaudited)			Half year ended (Unaudited)		Year ended (Audited)
	30-Sep-2012	30-Jun-2012	30-Sep-2011	30-Sep-2012	30-Sep-2011	31-Mar-2012
Income from operations						
Net sales (Net of excise duty) (see note 3)	74717	73560	65596	148277	126694	259441
Other operating income	3005	3131	2892	6136	6013	10151
Total income from operations (net)	77722	76691	68488	154413	132707	269592
Expenses						
Cost of materials consumed	21222	20292	15952	41514	31582	65118
Purchases of stock-in-trade	7466	6444	6050	13910	11484	21534
Changes in Inventories of finished goods, work-in-progress and stock-in-trade	(6996)	(4740)	209	(11736)	(1265)	(340)
Employee benefits expense	15554	15306	12983	30860	25570	53372
Depreciation and amortisation expense	2029	2013	2007	4042	4026	8173
Other expenses	24943	23793	18927	48736	35952	79843
Total expenses	64218	63108	56138	127326	107349	227700
Profit from operations before other income, finance costs and exceptional items	13504	13583	12350	27087	25358	41892
Other income	1232	1402	839	2634	1986	4451
Profit from ordinary activities before finance costs and exceptional items	14736	14985	13189	29721	27344	46343
Finance costs	798	942	997	1740	2019	3945
Profit from ordinary activities after finance costs but before exceptional items	13938	14043	12192	27981	25325	42398
Exceptional item	-	-	-	-	-	6536
Profit from ordinary activities before tax	13938	14043	12192	27981	25325	35862
Tax expense	3091	3739	2115	6830	4989	7232
Net Profit for the period	10847	10304	10077	21151	20336	28630
Minority interest	122	119	78	241	85	226
Net Profit after taxes and minority interest	10725	10185	9999	20910	20251	28404
Paid-up equity share capital (Face value of Rs. 5 each)	4231	4231	4231	4231	4231	4231
Reserves excluding Revaluation Reserves	-	-	-	-	-	115151
Earnings per share (of Rs. 5/- each) (not annualised):						
Basic	12.67	12.04	11.81	24.71	23.93	33.57
Diluted	12.67	12.04	11.81	24.71	23.93	33.57



PART II Select Information for the Quarter and Half Year Ended 30-Sep-2012						
PARTICULARS OF SHAREHOLDING	Quarter ended			Half Year ended		Year ended
	30-Sep-2012	30-Jun-2012	30-Sep-2011	30-Sep-2012	30-Sep-2011	31-Mar-2012
Public shareholding						
- Number of shares	24109500	24109500	24109500	24109500	24109500	24109500
- Percentage of shareholding	28.49%	28.49%	28.49%	28.49%	28.49%	28.49%
Promoters and Promoter Group Shareholding						
(a) Pledged / Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
(b) Non - encumbered						
- Number of shares	60501860	60501860	60501860	60501860	60501860	60501860
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	71.51%	71.51%	71.51%	71.51%	71.51%	71.51%
INVESTOR COMPLAINTS	Quarter ended					
	30-Sep-2012					
Pending at the beginning of the quarter	Nil					
Received during the quarter	1					
Disposed of during the quarter	1					
Remaining unresolved at the end of the quarter	Nil					

Notes:

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 26-Oct-2012. The statutory auditors have carried out limited review of the results for the quarter and half year ended 30-Sep-2012. There is no adverse observation in the limited review report on this statement of financial results.
- The statement of financial results consolidate the financial results of fifteen wholly owned subsidiaries and two partnership firms with that of the Company.
- The Company operates a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

(Rs. in Lacs)

Particulars	Quarter ended (Unaudited)			Half year ended (Unaudited)			Year ended (Audited)
	30-Sep-2012	30-Sep-2011	Growth %	30-Sep-2012	30-Sep-2011	Growth %	31-Mar-2012
(A) Sales in India							
Branded sales	27425	23848	15%	55448	48491	14%	91670
Contract manufacture	5633	5514	2%	10384	11647	(11%)	24271
Others	126	164	-	378	223	-	658
Total sales in India	33184	29526	12%	66210	60361	10%	116599
(B) Sales outside India	41733	36199	15%	82438	66556	24%	143322
Total sales (A+B)	74917	65725	14%	148648	126917	17%	259921
Less: Excise duty	200	129	-	371	223	-	480
Net sales	74717	65596	14%	148277	126694	17%	259441



4 Consolidated Statement of Assets and Liabilities

[Rs. in Lacs]

Particulars	Unaudited	Audited
	As at 30-Sep-2012	As at 31-Mar-2012
EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	4231	4231
Reserves and surplus	140104	115151
Sub-total - Shareholders' funds	144335	119382
Minority interest	562	350
Non-current liabilities		
Long-term borrowings	23922	32206
Deferred tax liabilities (net)	6112	7709
Other long-term liabilities	616	380
Long-term provisions	12067	11045
Sub-total - Non-current liabilities	42717	51340
Current liabilities		
Short-term borrowings	6546	13812
Trade payables	79025	86345
Other current liabilities	29534	29100
Short-term provisions	7241	7025
Sub-total - Current liabilities	122346	136282
TOTAL - EQUITY AND LIABILITIES	309960	307354
ASSETS		
Non-current assets		
Fixed assets	102146	91564
Non-current investments	3752	3752
Deferred tax assets (net)	1179	2565
Long-term loans and advances	5192	6137
Other non-current assets	1824	4625
Sub-total - Non-current assets	114093	108643
Current assets		
Current investments	8125	8652
Inventories	73501	53155
Trade receivables	56087	52280
Cash and cash equivalents	38132	67428
Short-term loans and advances	6603	5646
Other current assets	13419	11550
Sub-total - Current assets	195867	198711
TOTAL - ASSETS	309960	307354

5 Summary details of stand-alone audited financial results of Torrent Pharmaceuticals Limited :

[Rs. in Lacs]

Particulars	Quarter ended			Half year ended		Year ended
	30-Sep-2012	30-Jun-2012	30-Sep-2011	30-Sep-2012	30-Sep-2011	31-Mar-2012
Net sales & operating income	68892	64910	50623	133802	101306	207604
Profit before tax	19020	17481	8879	36501	21388	37070
Profit after tax	16211	14752	7023	30963	16967	31125

6 The figures for the comparative periods have been regrouped, wherever necessary, to make them comparable with the figures for the current periods.

7 The standalone audited financial results for the quarter and half year ended 30-Sep-2012 are available on the Company's website at www.torrentpharma.com.

Place : Dahej, Gujarat
Date : 26-Oct-2012



Visit us at www.torrentpharma.com....

For TORRENT PHARMACEUTICALS LIMITED

SAMIR MEHTA
Executive Vice Chairman

Torrent Pharma records 13% growth in Revenues during Q2 12-13

Ahmedabad-based Torrent Pharmaceuticals Limited, today released its financial results for the quarter ended 30th September, 2012. The Q2' 12-13 revenues stood at ₹ 777 crores, up by 13% from ₹ 685 crores in the comparable quarter of last year.

During Q2, domestic formulation business recorded revenues of ₹ 274 crores, growing by 15%. International revenues grew by 15% to ₹ 417 crores. Operations in Brazil registered revenue de-growth of 7%. During the quarter, there was a strike by the Brazilian regulatory organization (ANVISA), which affected clearance of the goods from the ports. Revenues from the US operations recorded growth of 80% while business from Europe (other than Heumann), Russia & CIS and Rest of the World recorded a growth of 17%.

Profit before Taxes for the quarter grew by 14% to ₹ 139 crores compared to ₹ 122 crores during the same period last year.

For H1, the revenues increased by 16% to ₹ 1,544 crores compared with ₹ 1,327 crores for the corresponding period last year. During H1, Profit before Taxes grew by 11% to ₹ 280 compared to ₹ 253 crores during the same period last year.

The total revenue expenditure on R&D was 5% of consolidated net sales and operating income.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over ₹ 2,650 crores is the flagship company of the Torrent Group. With many of its products ranking among the Top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthrough discoveries in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 640 scientists in the areas of drug discovery and development. Currently, Torrent has various discovery projects in pipeline. It has filed 450 patents for NCEs in all major markets worldwide, of which 211 patents have been granted so far. Torrent's manufacturing plant at Chatral has a capacity to manufacture approx. 5,500 million Tablets, capsules and vials and 45,000 kgs. of Bulk Drugs/API. The facility has already been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 3,300 million tablets and 350 million capsules. The newly constructed manufacturing plant at Sikkim has a capacity to manufacture 3,900 million tablets per annum.

